WDNA241220C20000
- 0.00
- 0.000.00%
WISDOMTREE BIOREVOLUTION FUND Newsroom
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
12 Health Care Stocks Moving In Monday's Pre-Market Session
Analyst Expectations For Natera's Future
Natera Analyst Ratings
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript Summary
Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock
Veracyte Analyst Ratings
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Top Wall Street Forecasters Revamp Twist Bioscience Price Expectations Ahead Of Q4 Earnings
Twist Bioscience Expects Q1 2025 Sales Of ~$87M Vs. Consensus Of $84.473M
Twist Bioscience GAAP EPS of -$0.59 Beats by $0.11, Revenue of $84.71M Beats by $2.05M
Eli Lilly's Tirzepatide Cuts Risk of Worsening Heart Failure in HFpEF, Obese Patients
Earnings Scheduled For November 18, 2024
Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
What kind of company is Natera, the largest hold positions of Drew Miller?
Currently, there is a lack of precision in adjuvant therapy plans after tumor (MRD) surgery, while MRD testing can detect molecular abnormalities originating from the tumor, enabling early detection of cancer recurrence and guiding precise postoperative treatment. Huayuan Securities believes that natera's MRD testing business has significant competitive advantages, and its launched Signatera product is expected to become the core driving force behind the company's rapid performance improvement.
Weekly Buzz: Not All Parties Last Forever